IAS 2025: ANRS MIE-supported research projects selected this year

From 13 to 17 July 2025

Main points

The IAS (International AIDS Society) conference will not only highlight major advances in research and innovations in the field of HIV, but will also address the political and financial issues currently affecting the fight against HIV/AIDS in Africa and the rest of the world.

IAS 2025 programme

  • Objective 1: Highlight the latest scientific advances, particularly the significant contributions of African scientists in the fight against the epidemic on the continent most affected by HIV.
  • Objective 2: Collect research results, from basic to implementation sciences, to address the priorities of affected communities under the control of those most affected.
  • Objective 3: Accelerate innovation in basic and clinical sciences for personalised medicine, including research on transmission reduction, vaccine development, understanding pathogenesis, management of co-infections and co-morbidities, addressing ageing-related issues and progress towards a cure for HIV.
  • Goal 4: Strengthen HIV prevention research to optimise the cost-effectiveness of biomedical, behavioural and structural interventions, with a particular focus on identifying and addressing implementation challenges, removing barriers and scaling up effective prevention strategies in practice.
  • Target 5: Promote interdisciplinary collaboration between biomedical, clinical, social and implementation sciences to improve clinical outcomes across the life course, while highlighting the practical implications of this research.

IAS 2025: Oral presentations of projects funded by ANRS MIE

Fatoumata Fadiga, et al.

First experience of dual antiretroviral maintenance regimen in West and Central Africa compared with continuing 3-drug current antiretroviral regimens (CARs): Week 96 results from the MODERATO trial (ANRS -MIE 12372)

Affiliation 1er auteur : PAC-CI-PRISME-CI, Abidjan, Côte d’Ivoire

Luis Sagaon-Teyssier, et al.

HIV transmission risk, sexual and mobility behaviors among men, women, and female sex workers living with HIV in informal gold mining sites in Mali: the ANRS-12392 – Sanu Gundo study

Affiliation 1er auteur : IRD, Aix Marseille Univ, Inserm, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille

Marion Fiorentino, et al.

Exposure to violence among transgender women living with HIV in France, engaged or not in sex work: results from the national ANRS-14056 TRANS&VIH study

Affiliation 1er auteur : IRD, Aix Marseille Univ, Inserm, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille

Cécile Herate, et al.

Efficacy of Modified-Vaccinia Ankara Vaccine as Pre-Exposure and Post-Exposure Prophylaxis Against Monkeypox Sexual Transmission in Non-Human Primate model

Affiliation 1er auteur : Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Viral Diseases (IMVA-HB/IDMIT), IDMIT, Fontenay-aux-Roses

Romain Silhol, et al.

Modelling the potential detrimental impact of ongoing US government financial support withdrawals on HIV in Western Africa (ANRS 0792): preliminary results

Affiliation 1er auteur : Imperial College London, London, United Kingdom

S. Abdalla, et al.

Pharmacokinetic modeling to support WHO-weight band dosing of the new pediatric Darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children

James Wyncoll, et al.

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial

Pauline Amuge, et al.

Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials

Man K. Chan, et al.

Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY Trial

IAS 2025 : Posters des travaux financés par l’ANRS MIE

Daniel Kashnitsky, et al.

(Re)producing HIV Care for Ukrainian Refugees in Germany and Poland: Trans-local Community-based Support in Action

Affiliation 1er auteur : Paris Cité, Cermes3 laboratory, Paris

Clément Boutet, et al.

A competing risks duration model to study PrEP discontinuation among MSM in France: The ERAS 2023 study

Affiliation 1er auteur : Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille

Marion Fiorentino, et al.

High prevalence of genital diseases among young female domestic workers in Mali and the role of community-based support in promoting sexual health: the ANRS-0005S 2DM2K project

Affiliation 1er auteur : IRD, Aix Marseille Univ, Inserm, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille

Fatoumata Fadiga, et al.

Evolution of weight under Dual Therapy Compared to Triple Therapy: Week 96 Results from the MODERATO Trial (ANRS -MIE 12372)

Affiliation 1er auteur : PAC-CI-PRISME-CI, Abidjan, Côte d’Ivoire

Grace Ahimbisibwe, et al.

Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert

Topics specifically addressed during IAS 2025

The impact of budget cuts

The latest budget cuts are jeopardising decades of progress in the global fight against HIV, with the following examples supporting this regression:

  • Real-life data from Mozambique show that budget cuts have affected HIV treatment services. They also show how they could change HIV incidence and mortality through 2030.
  • Modélisation de l’effet prévu des coupes budgétaires sur l’incidence et la mortalité liées au VIH en Afrique occidentale, et évaluation des effets de l’accès à la prophylaxie pré-exposition (PrEP) sur l’incidence du VIH parmi les populations vulnérables en Afrique centrale, orientale, australe et occidentale
  • Rapports en provenance d’organisations de 13 pays d’Amérique latine relatant l’impact des réductions budgétaires sur la lutte contre le VIH

Médicaments à action prolongée

IAS 2025 will highlight progress in the field of long-acting injectable medicines, which could contribute to ending the HIV pandemic as a threat to public health and individual well-being. The following topics will be presented: